CLINICAL AREA

Sulodexide and chronic venous disease

Chronic venous disease is the most clinically studied area of sulodexide research. The honest summary contains both halves: a positive multicentre ulcer-healing trial, and a Cochrane review rating the underlying evidence low quality. This page displays them together — the trial signal and the evidence limitation.

The trial signal

Published human trialModerate

Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers

Coccheri S, et al. · Thrombosis and Haemostasis, 87(6):947–952 · 2002

doi:10.1055/s-0037-1613116 ↗ · PMID 12083500

Design: Randomized, double-blind, multicentre, placebo-controlled
Participants / model: 235
Intervention: Sulodexide plus standard local care/compression for 3 months
Comparator: Placebo plus standard local care/compression
Endpoint: Complete ulcer healing
Result: Higher complete healing at 2 months (p=0.018) and 3 months; NNT 7 (2 months) and 5 (3 months); ulcer-area reduction and fibrinogen decrease in the sulodexide arm only.
Limitations: 3-month horizon; no long-term recurrence data in the abstract. Bibliographic note: the DOI was assigned retrospectively by Crossref; the PubMed record carries no DOI.
Conflicts: None declared in the verified record.

Panacea interpretation · A real signal, displayed together with the Cochrane limitation (S12) — one does not exist on this page without the other.

The evidence limitation

The Cochrane review found that sulodexide as an adjuvant might improve ulcer healing — on low-quality evidence, with adverse effects uncertain. A positive trial and a cautious systematic review are not a contradiction; they are the same evidence base seen at two levels of scrutiny.

Systematic reviewLow-quality evidence base (Cochrane)

Sulodexide for treating venous leg ulcers

Wu B, Lu J, Yang M, Xu T · Cochrane Database of Systematic Reviews, (6):CD010694 (update of 2014 original) · 2016

doi:10.1002/14651858.CD010694.pub2 ↗ · PMID 27251175

Design: Cochrane systematic review and meta-analysis (4 RCTs)
Participants / model: 4 RCTs, 463 participants (3 RCTs in the meta-analysis)
Intervention: Sulodexide as adjuvant to local care
Comparator: Local care alone
Endpoint: Complete ulcer healing; adverse events
Result: Complete healing 49.4% (sulodexide adjuvant) vs 29.8% (local care alone), RR 1.66 (95% CI 1.30–2.12) — rated LOW quality (risk of bias). Adverse events 4.4% vs 3.1%, RR 1.44 (95% CI 0.48–4.34) — VERY LOW quality; unclear whether sulodexide is associated with any increase in adverse events.
Limitations: Few small trials, high risk of bias (one abstract-only); dosing/route unclear; conclusions likely to change with new research.
Conflicts: None declared in the verified record.

Panacea interpretation · The evidence limitation: sulodexide might improve ulcer healing, on low-quality evidence, with adverse effects uncertain. This page does not hide it.

Symptoms and signs, aggregated

Systematic reviewModerate

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Bignamini AA, Matuška J · Advances in Therapy, 37(3):1013–1033 · 2020

doi:10.1007/s12325-020-01232-1 ↗ · PMID 31989486

Design: Systematic review and meta-analysis
Participants / model: 23 studies / 7,153 participants; 13 studies (1,901 participants) with extractable quantitative data
Intervention: Sulodexide, various regimens
Comparator: Various comparators
Endpoint: Symptoms and signs of chronic venous disease; adverse events
Result: Reduced pain, cramps, heaviness, oedema, total symptom score and inflammatory mediators; adverse-event risk not different vs comparator (RR 1.31, 95% CI 0.74–2.32); overall adverse-event rate ~3%.
Limitations: Of 64 identified studies only 13 had extractable quantitative data — a thin, heterogeneous evidence base.
Conflicts: None declared in the verified record.

Panacea interpretation · Supports chronic venous disease as the most clinically studied area — with a visibly thin quantitative base.

Recurrent venous thromboembolism: SURVET

SURVET studied sulodexide for secondary prevention after 3–12 months of completed conventional anticoagulation for a first unprovoked VTE. It is not a treatment study for active VTE, and it is not permission to substitute prescribed anticoagulation.

Published human trialModerate (single large RCT)

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Andreozzi GM, Bignamini AA, et al. · Circulation, 132(20):1891–1897 · 2015

doi:10.1161/CIRCULATIONAHA.115.016930 ↗ · PMID 26408273

Design: Multicentre, randomized, double-blind, placebo-controlled (EudraCT 2009-016923-77)
Participants / model: 615 (307 sulodexide / 308 placebo)
Intervention: Sulodexide 500 LRU twice daily for 2 years, after 3–12 months of conventional anticoagulation for a first unprovoked VTE
Comparator: Placebo
Endpoint: Recurrent venous thromboembolism
Result: Recurrence 15/307 vs 30/308 (HR 0.49; 95% CI 0.27–0.92; p=0.02). No major bleeding; 2 clinically relevant bleeds per arm.
Limitations: Applies only to extended secondary prevention after completed conventional anticoagulation for a first unprovoked VTE — not treatment of active VTE, and not permission to substitute prescribed anticoagulation.
Conflicts: None declared in the verified record.

Panacea interpretation · A well-defined clinical context: secondary prevention after completed anticoagulation, nothing broader.

THE FULL EVIDENCE DATABASE POST-VIRAL ENDOTHELIUM